Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Characterization of Novel Influenza Virus-Like Particle's Mechanism of Action in Dendritic Cells

EF 2016-17

Résumé
Influenza is a respiratory illness severely affecting 3 to 5 million individuals every year. Annual influenza vaccines are an important preventative measure to reduce the morbidity and mortality associated with the virus. Although humoral responses have been used as the principal measure of vaccine efficacy, cell-mediated responses are now appreciated as an important measure of a vaccine's potency. An influenza virus-like particle (VLP), a novel, non-infectious and potent nanoparticle vaccine has been observed to elicit both effective cell-mediated and humoral immune responses in human pre-clinical trials. Because cell-mediated immunity depends on efficient antigen-presentation by innate immune cells, the effect of the VLPs on dendritic cells (DCs), professional antigen presenting cells, is of key interest. The VLPs have been seen to stimulate DCs and elicit cytotoxic T cell responses, evidence of cross-presentation by the DCs, but the mechanism by which the VLPs act is unknown. With murine bone-marrow dendritic cell cultures and human monocyte-derived dendritic cells, I will study the effect of the VLP. Using Western blot, flow cytometry and ELISA, I will investigate the mechanism of action of the VLPs. Understanding the mechanism of the innate stimulatory effect of the VLP will offer greater insight into eliciting a more potent cell-mediated immune response for greater protective immunity by this novel and easily manufactured vaccine.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
367408
Name
Won So Yoon
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Characterization of Novel Influenza Virus-Like Particle's Mechanism of Action in Dendritic Cells
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bone Marrow-Derived Dendritic Cells; Cell-Mediated Immunity; Elisa; Flow Cytometry; In Vitro Cell Culture; Influenza; Monocyte-Derived Dendritic Cells; Signaling Pathway Mechanism; Vaccine; Virus-Like Particle
Abstract
Influenza is a respiratory illness severely affecting 3 to 5 million individuals every year. Annual influenza vaccines are an important preventative measure to reduce the morbidity and mortality associated with the virus. Although humoral responses have been used as the principal measure of vaccine efficacy, cell-mediated responses are now appreciated as an important measure of a vaccine's potency. An influenza virus-like particle (VLP), a novel, non-infectious and potent nanoparticle vaccine has been observed to elicit both effective cell-mediated and humoral immune responses in human pre-clinical trials. Because cell-mediated immunity depends on efficient antigen-presentation by innate immune cells, the effect of the VLPs on dendritic cells (DCs), professional antigen presenting cells, is of key interest. The VLPs have been seen to stimulate DCs and elicit cytotoxic T cell responses, evidence of cross-presentation by the DCs, but the mechanism by which the VLPs act is unknown. With murine bone-marrow dendritic cell cultures and human monocyte-derived dendritic cells, I will study the effect of the VLP. Using Western blot, flow cytometry and ELISA, I will investigate the mechanism of action of the VLPs. Understanding the mechanism of the innate stimulatory effect of the VLP will offer greater insight into eliciting a more potent cell-mediated immune response for greater protective immunity by this novel and easily manufactured vaccine.
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
Won, So Yoon
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~